• Arvinas posted a net loss of USD 57.6 million, swinging from net income of USD 82.9 million a year earlier as revenue fell 91.74% to USD 15.6 million.
• Research and development expense dropped 33.59% to USD 60.3 million, while general and administrative expense declined 28.2% to USD 19.1 million.
• Cash, cash equivalents and marketable securities totaled USD 614.9 million as of March 31, 2026; Arvinas said this should fund operations into the second half of 2028.
• FDA approved VEPPANU (vepdegestrant) in the second quarter, triggering a USD 50 million development milestone payment under the Pfizer collaboration that will be offset by amounts owed to Yale.
• Pipeline updates included ARV-102 Phase 1b U.S. PSP trial on clinical hold pending final non-human primate chronic tox data expected mid-2026, with a second-half 2026 start targeted; ARV-806 completed Phase 1 dose escalation, with initial clinical data expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-033669), on May 11, 2026, and is solely responsible for the information contained therein.